Drug Profile

BX 001

Alternative Names: BX-001

Latest Information Update: 15 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BiomX; Unknown
Class Antiacnes; Antibacterials; Bacteriophages
Mechanism of Action Cell death stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Acne vulgaris

Most Recent Events

15 Nov 2022 Discontinued - Phase-II for Acne vulgaris in Israel (Topical)
24 May 2021 BiomX completes enrolment in a phase II cosmetic clinical trial for Acne vulgaris in Israel (Topical)
02 Mar 2021 Phase-II clinical trials in Acne vulgaris in Israel (Topical)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com